Don’t delay: Cancer patients need both doses of COVID vaccineMarch 15, 2021Patient & Survivor CareDLBCLCOVID-19 UpdatesBreast CancerCNS/Brain CancerFollicular LymphomaGastrointestinal Cancer
Novel ddPCR assay precisely measures CAR T-cells after infusionFebruary 22, 2021DLBCLFollicular LymphomaLymphoma & Plasma Cell Disorders
Steroid complications in GVHD common, boost costs of careFebruary 19, 2021DLBCLLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
CAR T-cell products shine in real-world setting, reveal new insightsFebruary 18, 2021DLBCLLymphoma & Plasma Cell Disorders
Chronic GVHD therapies offer hope for treating refractory diseaseFebruary 17, 2021Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersDLBCL
Prognostic gene signature identifies high- vs. low-risk DLBCL patientsFebruary 17, 2021DLBCLLymphoma & Plasma Cell Disorders
Synthetic lethality: Triple combination is a viable strategy for B-cell malignanciesDecember 11, 2020DLBCLLymphoma & Plasma Cell Disorders
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHLDecember 10, 2020Lymphoma & Plasma Cell DisordersDLBCL
Seven things to know about new lymphoma drug tafasitamabOctober 9, 2020DLBCLLymphoma & Plasma Cell Disorders
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020COVID-19 UpdatesBreast CancerCNS/Brain CancerDLBCLFollicular LymphomaLung CancerLeukemia, Myelodysplasia, Transplantation
FDA approves selinexor for relapsed/refractory DLBCLJune 23, 2020DLBCLLymphoma & Plasma Cell Disorders
Race and location appear to play a role in the incidence of CLL and DLBCLMay 20, 2020DLBCLLeukemia, Myelodysplasia, Transplantation
